A STUDY OF BEVACIZUMAB (AVASTIN) IN NEOADJUVANT THERAPY IN PARTICIPANTS WITH INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS (FIGO) STAGE IIIC/IV OVARIAN, TUBAL, OR PERITONEAL CANCER, INITIALLY UNRESECTABLE: